EGFR/CDK2-IN-3 (compound 4b) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 71.7 nM and 113.7 nM, respectively. It prompts apoptosis in MCF-7 cells and halts the cell cycle in the S phase while demonstrating substantial anti-cancer cell toxicity, inhibiting MCF-7 cells with an IC50 of 3.16 μM [1].